CHRISTIAN TAKAYAMA: Open Payments
NPI 1992968648 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,811 in 66 payments from 6 companies in 2025. Trend: 2023 $1,722 · 2024 $2,212 · 2025 $1,811
Food & beverage: $1,811
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 35 | $1,007 |
| ViiV Healthcare Company | 16 | $414 |
| Merck Sharp & Dohme LLC | 7 | $175 |
| Napo Pharmaceuticals Inc | 4 | $103 |
| ABBVIE INC. | 3 | $87 |
| GlaxoSmithKline, LLC. | 1 | $24 |
Products named: CABENUVA, PIFELTRO, APRETUDE, Mytesi, Biktarvy, MAVYRET, DOVATO, GARDASIL 9.
Industry payments across CA — which companies pay providers there.
